Anemia of Chronic Diseases

Hematology: Basic Principles and Practice

Volumn , Issue , 2018, Pages 491-496

  Nayak, Lalitha ^a   Gardner, Lawrence B ^b   Little, Jane A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anemia; Cancer; Chronic disease; Erythropoietin; Hepcidin; Inflammation; Iron

Indexed keywords

EID: 85055842427     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-35762-3.00037-8     Document Type: Chapter

References (26)

1. Weiss G, Goodnough LT Anemia of chronic disease. New Engl J Med 2005, 352:1011-1023.
2. Nairz M, Haschka D, Demetz E, et al. Iron at the interface of immunity and infection. Front Pharmacol 2014, 5:152.
3. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306:2090-2093.
4. Theurl I, Mattle V, Seifert M, et al. Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood 2006, 107:4142-4148.
5. Sun CC, Vaja V, Babitt JL, et al. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol 2012, 87:392-400.
6. Thomas C, Thomas L Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol 2005, 11:14-23.
7. Theurl I, Theurl M, Seifert M, et al. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood 2008, 111:2392-2399.
8. Raj DS Role of interleukin-6 in the anemia of chronic disease. Semin Arthritis Rheum 2009, 38:382-388.
9. Andrews NC Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 2004, 113:1251-1253.
10. Oppenheimer SJ Iron and its relation to immunity and infectious disease. J Nutr 2001, 131:616S-633S.
11. Ganz T Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003, 102:783-788.
12. Fleming RE, Sly WS Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci USA 2001, 98:8160-8162.
13. Wrighting DM, Andrews NC Interleukin-6 induces hepcidin expression through STAT3. Blood 2006, 108:3204-3209.
14. Richardson CL, Delehanty LL, Bullock GC, et al. Isocitrate ameliorates anemia by suppressing the erythroid iron restriction response. J Clin Invest 2013, 123:3614-3623.
15. Bullock GC, Delehanty LL, Talbot AL, et al. Iron control of erythroid development by a novel aconitase-associated regulatory pathway. Blood 2010, 116:97-108.
16. de Bruin AM, Demirel O, Hooibrink B, et al. Interferon-gamma impairs proliferation of hematopoietic stem cells in mice. Blood 2013, 121:3578-3585.
17. Ashby DR, Gale DP, Busbridge M, et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 2010, 95:505-508.
18. Kautz L, Jung G, Nemeth E, et al. Erythroferrone contributes to recovery from anemia of inflammation. Blood 2014, 124:2569-2574.
19. Cullis JO Diagnosis and management of anaemia of chronic disease: current status. Brit J Haematol 2011, 154:289-300.
20. Skikne BS, Punnonen K, Caldron PH, et al. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol 2011, 86:923-927.
21. Brugnara C, Schiller B, Moran J Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. Clin Lab Haematol 2006, 28:303-308.
22. Viele MK, Weiskopf RB What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah's Witnesses. Transfusion 1994, 34:396-401.
23. Samaras AT, Bennett CL Risks of venous thromboembolism and mortality associated with erythropoiesis-stimulating agents for the treatment of cancer-associated anemia. Am J Hematol Oncol 2008, 7:327-332.
24. Sanz Ortiz J Predictors of response to erythropoiesis-stimulating agents (ESA) in cancer patients: the role of baseline serum epoetin level. Clin Transl Oncol 2008, 10:486-492.
25. Sasu BJ, Cooke KS, Arvedson TL, et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 2010, 115:3616-3624.
26. Song SN, Tomosugi N, Kawabata H, et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 2010, 116:3627-3634.